
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions β written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Hypopituitarism natural history, complications and prognosis
Introduction
Overview
Overview
The natural history of hypopituitarism depends on the severity of damage leading to partial or complete hormonal deficiency. If left untreated, hypopituitarism can lead to critical consequences. Complications of hypopituitarism include adrenal crisis, osteoporosis, electrolyte abnormalities, and diabetes mellitus. Hypopituitarism is often associated with vascular conditions. Hypopituitarism has a good prognosis as long as the hormonal replacement therapy is given adequately.
Natural History
Natural History
If left untreated, hypopituitarism may lead to the development of different symptoms according to the area/lobe of the pituitary gland affected and the deficient hormone. The natural history is variable and depends upon the severity of damage leading to partial or complete hormonal deficiency, age, rapidity of onset, and the underlying cause:[1]
- In both genders, if left untreated, it will lead to a decrease in bone density and osteoporosis.[2][3][4]
- In women, there may be an increased risk of coronary artery disease due to a reduction estrogen levels.[5][6]
- In men, decreased muscle mass due to a reduction in testosterone hormone levels.
Vasopressin deficiency
- It may lead to dehydration and electrolyte abnormalities such as hypernatremia.
Growth hormone deficiency
- It may lead to serious vascular conditions most likely due to increased serum cholesterol and triglyceride concentrations causing increased mortality.[7][8][9]
Complications
Complications
Complications that can develop as a result of hypopituitarism are include:
- Adrenal crisis, the most serious complication of hypopituitarism. It occurs in case of improper glucocorticoids replacement therapy.
- Complications of growth hormone replacement therapy:[10]
Prognosis
Prognosis
- Hypopituitarism has a good prognosis as long as the patient is given optimum hormonal replacement therapy.[1]
- Hypopituitarism is often associated with vascular conditions and has a high mortality rate.[11]
- There are 6 major retrospective studies done that have shown increased mortality in patients with hypopituitarism.[7][12][13][14][15]
References
References
- β 1.0 1.1 Vance, Mary Lee (1994). “Hypopituitarism”. New England Journal of Medicine. 330 (23): 1651β1662. doi:10.1056/NEJM199406093302306. ISSNΒ 0028-4793.
- β Klibanski, Anne; Neer, Robert M.; Beitins, Inese Z.; Ridgway, E. Chester; Zervas, Nicholas T.; McArthur, Janet W. (1980). “Decreased Bone Density in Hyperprolactinemic Women”. New England Journal of Medicine. 303 (26): 1511β1514. doi:10.1056/NEJM198012253032605. ISSNΒ 0028-4793.
- β Greenspan SL, Oppenheim DS, Klibanski A (1989). “Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism”. Ann. Intern. Med. 110 (7): 526β31. PMIDΒ 2923387.
- β Klibanski A, Neer RM, Beitins IZ, Ridgway EC, Zervas NT, McArthur JW (1980). “Decreased bone density in hyperprolactinemic women”. N. Engl. J. Med. 303 (26): 1511β4. doi:10.1056/NEJM198012253032605. PMIDΒ 7432421.
- β Matthews, Karen A.; Meilahn, Elaine; Kuller, Lewis H.; Kelsey, Sheryl F.; Caggiula, Arlene W.; Wing, Rena R. (1989). “Menopause and Risk Factors for Coronary Heart Disease”. New England Journal of Medicine. 321 (10): 641β646. doi:10.1056/NEJM198909073211004. ISSNΒ 0028-4793.
- β Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR (1989). “Menopause and risk factors for coronary heart disease”. N. Engl. J. Med. 321 (10): 641β6. doi:10.1056/NEJM198909073211004. PMIDΒ 2488072.
- β 7.0 7.1 RosΓ©n T, Bengtsson BA (1990). “Premature mortality due to cardiovascular disease in hypopituitarism”. Lancet. 336 (8710): 285β8. PMIDΒ 1973979.
- β Merimee TJ, Hollander W, Fineberg SE (1972). “Studies of hyperlipidemia in the HGH-deficient state”. Metab. Clin. Exp. 21 (11): 1053β61. PMIDΒ 4342932.
- β Blackett PR, Weech PK, McConathy WJ, Fesmire JD (1982). “Growth hormone in the regulation of hyperlipidemia”. Metab. Clin. Exp. 31 (2): 117β20. PMIDΒ 6804746.
- β Bowlby DA, Rapaport R (2004). “Safety and efficacy of growth hormone therapy in childhood”. Pediatr Endocrinol Rev. 2 Suppl 1: 68β77. PMIDΒ 16456485.
- β Prabhakar VK, Shalet SM (2006). “Aetiology, diagnosis, and management of hypopituitarism in adult life”. Postgrad Med J. 82 (966): 259β66. doi:10.1136/pgmj.2005.039768. PMCΒ 2585697. PMIDΒ 16597813.
- β Bates AS, Van’t Hoff W, Jones PJ, Clayton RN (1996). “The effect of hypopituitarism on life expectancy”. J. Clin. Endocrinol. Metab. 81 (3): 1169β72. doi:10.1210/jcem.81.3.8772595. PMIDΒ 8772595.
- β BΓΌlow B, Hagmar L, Mikoczy Z, NordstrΓΆm CH, Erfurth EM (1997). “Increased cerebrovascular mortality in patients with hypopituitarism”. Clin. Endocrinol. (Oxf). 46 (1): 75β81. PMIDΒ 9059561.
- β Nilsson B, Gustavasson-Kadaka E, Bengtsson BA, Jonsson B (2000). “Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality”. J. Clin. Endocrinol. Metab. 85 (4): 1420β5. doi:10.1210/jcem.85.4.6498. PMIDΒ 10770176.
- β Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Stewart PM (2001). “Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group”. Lancet. 357 (9254): 425β31. PMIDΒ 11273062.
β β
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]
